EMA: ABEL for HVD(P)s, PK metrics [Regulatives / Guidelines]

posted by Pharma_88 – India, 2020-09-08 11:05 (2119 d 08:28 ago) – Posting: # 21910
Views: 9,724

Thanks For your detailed response.

I have a few questions and need your suggestion in this regards.

I have kept following parameters in SS study (IR VS ER).

Primary pharmacokinetic parameters: AUC0-τ,ss
Secondary pharmacokinetic parameters:
Day 01 to 04-Morning dose: Cpd
Day 04 (Morning dose): Cτ,ss, Cmax,ss, Cmin,ss, Tmax,ss, accumulation index, %Fluctuation and Cav

Please correct me.

and also want to know for Cpd and Cτ,ss:

Cpd: All pre-dose samples needs to be considered including profiling day sample or only samples before profiling day?

Cτ,ss: How to calculate it? Whether morning dose of Day 04 is also need to be taken in to account to calculate.

Thanks.

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
366 visitors (0 registered, 366 guests [including 19 identified bots]).
Forum time: 19:33 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5